Semaglutide for Weight Loss
Vital IV Infusions Offers Semaglutide for Weight Loss Treatment in Chatham, NJ
Roughly two out of three U.S. adults are overweight or obese (69 percent) and one out of three are obese (36 percent). (Harvard School of Public Health)
At Vital IV, we understand the struggles many individuals face when trying to achieve weight loss and maintain it in the long term. Countless diets and exercise regimens may provide temporary results, but sustaining weight loss can be challenging. That’s where Semaglutide comes into play.
If you live in the Chatham, NJ, area and are looking for an alternative treatment for your weight loss journey, Vital IV can help. Contact us today and schedule your consultation.
If you live in the Chatham, NJ, area and are looking for an alternative treatment for your weight loss journey, Vital IV can help. Contact us today and schedule your consultation.
What is Semaglutide and how does it help with Weight Loss?
Semaglutide is a powerful drug that belongs to a group of medications called GLP1-RAs (glucagon-like peptide 1 receptor agonists). Originally designed for diabetes management, these drugs have also shown significant weight loss benefits. Among the GLP-1 RAs, Semaglutide has emerged as the most effective option for weight loss and has recently been granted FDA approval under the brand name Wegovy®. This breakthrough medication offers promising results in helping individuals with their weight loss journey.
How does Semaglutide work?
Semaglutide is a medication that replicates the sensation of being full, leading to a decrease in calorie intake. By reducing glucagon secretion in a glucose-dependent manner, Semaglutide also slows down the rate at which the stomach empties. This delay in gastric emptying can have several beneficial effects, such as reducing appetite, enhancing control over eating habits, and minimizing food cravings.
At Vital IV Infusions, we offer a variety of options for weight loss treatment in Chatham, NJ.
Are you a candidate for Semaglutide?
There are two qualifications for Semaglutide:
- A BMI over 30 and no weight-related complications
- A BMI over 27 with weight-related complications
Why is the weight loss goal 10%? What if I want to lose more weight?
The weight loss goal is backed by extensive clinical research, which has shown that losing 10% of your body weight and maintaining that loss can be achieved with the combination of an FDA-approved metabolic medication and accountability coaching. While many patients may experience even greater weight loss, the target of 10% is specifically chosen because it leads to significant improvements in various metabolic and inflammatory markers.
Research has demonstrated that a 10% reduction in body weight can have substantial benefits for cardiovascular health, such as lowering high blood pressure, cholesterol levels, and reducing the risk of developing diabetes. Furthermore, a 10% weight loss has been proven to alleviate symptoms associated with depression, arthritis, and sleep apnea while enhancing overall quality of life. Importantly, studies indicate that losing 10% of one’s body weight is both realistic and attainable for most individuals taking into account biological factors along with genetic predispositions and environmental influences.
Research has demonstrated that a 10% reduction in body weight can have substantial benefits for cardiovascular health, such as lowering high blood pressure, cholesterol levels, and reducing the risk of developing diabetes. Furthermore, a 10% weight loss has been proven to alleviate symptoms associated with depression, arthritis, and sleep apnea while enhancing overall quality of life. Importantly, studies indicate that losing 10% of one’s body weight is both realistic and attainable for most individuals taking into account biological factors along with genetic predispositions and environmental influences.
What will my food goals be?
- Creating a sustainable and adaptable approach to nutrition
- Reducing intake of fast-digesting carbs
- Making healthier choices by incorporating protein, fiber, and healthy fats into your diet without restricting or counting calories
Can I take additional weight loss medication, in addition to GLP-1s?
We do not recommend taking any weight loss medication that is not a GLP-1 during your weight loss program.
Is the medication safe?
GLP-1s are FDA-approved and safe. They have been widely used since 2005 and are generally very well tolerated, with minimal side effects.
Contraindications:
There are rare situations where Semaglutide is contraindicated. Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Does Semaglutide have side effects?
Most common side effects are: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, gas, stomach flu, and heartburn. Note that most of these are manageable by proper dosing and some overlap with the intended effect of “feeling full”.
- Getting the Inside Dope on Ketamine’s Mysterious Ability to Rapidly Relieve Depression – Scientific American (March 2018)
- Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study – Journal of Child and Adolescent Psychopharmacology (July 2018)
- Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression – American Journal of Psychiatry (Dec 2017)
- World-First Ketamine Trial Shows Promise For Geriatric Depression – American Journal of Geriatric Psychiatry (July 2017)
- FDA Data Support Ketamine as Depression Therapy – MedPage Today (May 2017)
- How Ketamine Infusion Will Transform the Way Depression is Treated – The Doctor Weighs In (July 2017)
- Club Drug Ketamine Gains Traction As A Treatment For Depression – NPR.org (Sept 2015)
- Ketamine may be quick, effective treatment for untreatable depression – CBS News (May 2013)
- The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review – National Center for Biotechnology Information (Sept 2014)
